August 19, 2011 -- Abcam plc (AIM: ABC), a global leader in the supply of protein research and detection tools, will announce its preliminary results for the 12 months ended 30 June 2011 on Tuesday 13 September 2011.
An analyst meeting will be held at 10.30am on Tuesday 13 September at the offices of Buchanan Communications, 107 Cheapside, London EC2V 6DN.
For further information please contact:
Abcam + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Jeff Iliffe, Chief Financial Officer
Numis Securities + 44 (0) 20 7260 1000
Michael Meade – Nominated Adviser
James Black – Corporate Broking
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Jessica Fontaine
About Abcam plc
Abcam is a producer and distributor of high quality research-grade antibodies and associated proteomics research products. Antibodies and related products are essential tools for life scientists enabling them to analyse components of living cells at the molecular level.
Headquartered in Cambridge (UK), Abcam has subsidiary offices in Cambridge, Massachusetts, and Eugene, Oregon (USA), Tokyo (Japan) and Hong Kong (China) allowing them to serve a global customer base of 75 countries. Abcam employs over 325 staff across its five operating companies.
Abcam now has an online catalogue of over 74,000 products sourced from over 250 suppliers. The catalogue includes a growing range of non-antibody products such as proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed e-commerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the leading provider of protein research and detection tools globally.